1. Home
  2. SEED vs CTXR Comparison

SEED vs CTXR Comparison

Compare SEED & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Agritech Limited

SEED

Origin Agritech Limited

HOLD

Current Price

$1.03

Market Cap

15.9M

ML Signal

HOLD

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.54

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEED
CTXR
Founded
1997
2007
Country
China
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.9M
18.9M
IPO Year
2005
2010

Fundamental Metrics

Financial Performance
Metric
SEED
CTXR
Price
$1.03
$0.54
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
26.3K
612.5K
Earning Date
01-30-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.38
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$0.48
52 Week High
$2.49
$2.24

Technical Indicators

Market Signals
Indicator
SEED
CTXR
Relative Strength Index (RSI) 42.13 39.91
Support Level $0.91 $0.48
Resistance Level $1.47 $0.74
Average True Range (ATR) 0.06 0.05
MACD -0.01 -0.00
Stochastic Oscillator 39.28 3.66

Price Performance

Historical Comparison
SEED
CTXR

About SEED Origin Agritech Limited

Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: